Abstract: A quantum measurement and control system and a quantum computer are disclosed.

Abstract: An information interaction method and apparatus, an electronic device and a storage medium are provided, the method comprising: displaying a preset first special effect element in a virtual reality space; determining whether a spatial relationship between a target control part controlled by a user and displayed in the virtual reality space and the first special effect element meets a preset condition; and in response to determining that the preset condition is met, displaying a second special effect associated with the first special effect element.

Abstract: A controller (600) for a radiotherapy device (320) is provided; the radiotherapy device (320) being configured to provide therapeutic radiation to a patient (308) via a source (300) of therapeutic radiation, wherein the radiotherapy device (320) comprises a first rotatable member (304), the rotation of which can alter a physical attribute of the therapeutic radiation provided, and a patient support member (310), which is linearly moveable in at least one of a longitudinal direction and a lateral direction. The controller (600) comprises a first rotatable actuator (608) for controlling a movement of the first rotatable member (304) and a second actuator (620) for controlling a movement of the patient support member (310).

Abstract: This invention disclosed an anti-HPV drug and its applications in preparing medicines for treatment of HPV (human papilloma virus) infection. This drug was characterized by using human rabies vaccine as its active ingredient and being produced by adding pharmacologically acceptable carriers. This invention also disclosed drug applications in preparing medicines for treatment of HPV infection, i.e. new applications of human rabies vaccines for preparing medicines against HPV infection. The anti-HPV drug described in this invention (i.e. human rabies vaccine) had obvious treatment effects on HPV infection. According to the animal tests and preclinical observation, this drug provided satisfactory and beneficial effects and had the characteristics of safety, effectiveness and nearly no recurrence after treatment; the negative-conversion rate in patients with positive HPV-infection reached 90% after treatment.